Importantly, inhibition of MDM2 and LSD1 induces cell death in MCC cells and reduces the growth of MCC tumor in mice, demonstrating the therapeutic potential of using MDM2 and LSD1 inhibitors in treating this highly aggressive skin cancer (Park et al., 2019, 2020; Leiendecker et al., 2020). Here, KDM1A is linked to skin cancer.